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Abstract
Predicting drug-target interactions (DTI) is an essential part of the drug discovery process,
which is an expensive process in terms of time and cost. Therefore, reducing DTI cost could
lead to reduced healthcare costs for a patient. In addition, a precisely learned molecule
representation in a DTI model could contribute to developing personalized medicine, which
will help many patient cohorts. In this paper, we propose a new molecule representation
based on the self-attention mechanism, and a new DTI model using our molecule represen-
tation. The experiments show that our DTI model outperforms the state of the art by up
to 4.9% points in terms of area under the precision-recall curve. Moreover, a study using
the DrugBank database proves that our model effectively lists all known drugs targeting a
specific cancer biomarker in the top-30 candidate list.
1. Introduction
Many diseases are caused by abnormal protein levels, therefore, a drug is designed to target
particular proteins. However, a drug may not work well for a decent portion of patients,
because an individual’s response to a drug varies depending on the genetic inheritance (Wang
et al., 2008). Unfortunately, pharmaceutical companies focus only on a majority cohort of
patients as drug discovery is an expensive process. The reduction of the cost of the drug
discovery process will not only lead to drugs costing less, resulting in reduced healthcare
costs for a patient but can also allow companies to develop personalized drugs based on
genetics.
Among the many parts of the drug discovery process, predicting drug-target interactions
(DTI) is an essential one. DTI is difficult and costly as experimental assays not only take
significant time but are expensive. Furthermore, only less than 10% of the proposed DTIs
are accepted as new drugs (He et al., 2017). Therefore, in silico (performed on a computer)
DTI predictions are much demanded since it can expedite the drug development process by
systemically suggesting a new set of candidate molecules promptly, which can save time and
reduce the cost of the whole process by up to 43% (DiMasi et al., 2016).
In response to this demand, three types of in silico DTI prediction methods have been
proposed in the literature: molecular docking, similarity-based, and deep learning-based
c© 2019 B. Shin§†, S. Park†, K. Kang‡† & J.C. Ho§.
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models. Molecular docking (Trott and Olson, 2010; Luo et al., 2016) is a simulation-based
method using the 3D structured features of molecules and proteins. Although it can provide
an intuitive visual interpretation, it is difficult to obtain a 3D structure of a feature and
cannot scale to large datasets. To mitigate these problems, two similarity-based methods,
KronRLS (Pahikkala et al., 2014) and SimBoost (He et al., 2017) have been proposed using
efficient machine learning methods. However, using a similarity matrix has two downsides.
Firstly, feature representation is limited in the similarity space, thereby ignoring the rich
information embedded in the molecule sequence. For example, if a brand new molecule is
tested, the model will represent it using relatively unrelated (dissimilar) molecules, which
would make the prediction inaccurate. Secondly, it necessitates the calculation of the sim-
ilarity matrix which can limit the maximum number of molecules in the training process.
To overcome these limitations, a deep learning-based DTI model, DeepDTA (Öztürk et al.,
2018), was proposed. It is an end-to-end convolutional neural network (CNN)-based model
that eliminates the need for feature engineering. The model automatically finds useful fea-
tures from a raw molecule and protein sequence. Its success has been demonstrated on two
publicly available DTI benchmarks. Although this work illustrated the potential of a deep
learning-based model, there are several areas for improvement:
• CNNs can’t model potential relationships among distant atoms in a raw molecule
sequence. For example, with three layers of CNNs each with a filter size of 12, the
model can capture associations in atoms up to 35 distances in a sequence. We posit that
the recently proposed self-attention mechanism can be used to capture any relationship
among atoms in a sequence, and thereby provide a better molecule relationship
• The one-hot encoding used to represent each molecule fails to take advantage of existing
chemical structure knowledge. An abundance of chemical compounds are available in
the PubChem database (Gindulyte et al., 2018), from which we can extract useful
chemical structures for pre-training the molecule representation network.
• Fine-tuning is a type of transfer learning where weights trained from one network can
be transferred to another so that the weights can be adjusted to the new dataset.
Thus, we can transfer the weights learned from the PubChem database to our DTI
model. This will help our model to use the learned knowledge of a chemical structure
while tailoring it to predicting DTI interactions.
With these observations, we propose a new deep DTI model, Molecule Transformer DTI
(MT-DTI), based on a new molecule representation. We use a self-attention mechanism
to learn the high-dimensional structure of a molecule from a given raw sequence. Our
self-attention mechanism, Molecular Transformer (MT), is pre-trained on publicly available
chemical compounds (PubChem database) to learn the complex structure of a molecule.
This pre-training is important, because most datasets available for DTI training has only
2000 molecules, while the data for pre-training (PubChem database) contains 97 millions of
molecules. Although it does not contain interaction data but just molecules, our MT is able
to learn a chemical structure from it, which will be effectively utilized when transferred to
MT-DTI (our model). Therefore, we transfer this trained molecule representation to our DTI
model so that it can be fine-tuned with a DTI dataset. The proposed DTI model is evaluated
on two well-known benchmark DTI datasets, Kiba (Tang et al., 2014) and Davis (Davis et al.,
2
MT-DTI
Multi-Layered
Protein
CNNs
Multi-Layered
Molecule
Transformers
CC(=O)OC1=CC=CC=C1C(=O)…
MARENGESSSSWKKQAEDIKK…
M-Rep
P-Rep
Multi-Layered 
Interaction
Dense Network
Affinity Score
M
-Rep
P-Rep
FASTA
SMILES
Figure 1: The Proposed DTI Model Architecture. Inputs are molecule
(SMILES) and protein (FASTA) and the regression output is the affinity
score between these two inputs.
2011), and outperforms the current state of the art (SOTA) model by 4.9% points for Kiba
and 1.6% points for Davis in terms of area under the precision-recall curve. Additionally, we
demonstrate the usefulness of our trained model using a known drug list targeting a specific
protein. The trained model generates all FDA approved drugs with high rankings in the
drug candidate lists. The demonstrated effectiveness of the proposed model can help reduce
the cost of drug discovery. Furthermore, precise molecule representation can enable drugs
to be designed for specific genotypes and potentially enable personalized medicine.
Technical Significance We propose a novel molecule representation, adapting the self-
attention mechanism that was recently proposed in Natural Language Process (NLP) liter-
ature. This is inspired by the idea that understanding a molecule sequence for a chemist is
analogous to understanding a language for a person. We introduce a new way to train the
molecule representation model to fit the DTI problem using an existing corpus to achieve a
more robust representation. With this (pre)trained molecule representation, we fine-tune the
proposed DTI model and achieve new SOTA performances on two public DTI benchmarks.1
Clinical Relevance With our new model, we can potentially lower medication costs for
patients, which can help make drugs more affordable and help patients be more adherent.
In addition, this can serve as the stepping stone for designing personalized medication.
Through the proper representation of molecules and proteins, we can better understand the
properties of patients that make a drug helpful or not (Quinn et al., 2017).
2. Methods
We introduce a new drug-target interaction (DTI) model and a new molecule representation
in this section. The basic motivation of the proposed model is that the structure of molecule
sequences is shown to be very similar to the structure of natural language sentences in that
contextual and structural information of atoms are important when understanding the char-
acteristics of a molecule (Jastrzębski et al., 2016). Specifically, each atom interacts with not
1. The demo is publicly available at
: https://mt-dti.deargendev.me/
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only neighboring atoms but also long distant one in a simplified molecular-input line-entry
system (SMILES) sequence, a notation that encodes the molecular structure of chemicals.
However, the current SOTA method using CNNs can’t relate long distance atoms when rep-
resenting a molecule. We overcome this using the self-attention mechanism. We first describe
the proposed MT-DTI model architecture (Figure 1) with input and output representation.
We then elaborate on each of the three main building blocks of our MT-DTI model, the
character-embedded Transformer layers (Molecule Transformers, Figure 2, Section 2.2), the
character-embedded Protein CNN layers (Protein CNNs, Figure 3, Section 2.3), and the
dense layers to model interactions between a drug and a protein (Interaction Denses, Fig-
ure 4, Section 2.4). Then, we explain the process for pre-training the molecule transformers
(MT) (Section 2.2).
2.1. Model Architecture
The MT-DTI model takes two inputs: a molecule represented by the SMILES (Weininger,
1988) sequence and a protein represented by the FASTA (Lipman and Pearson, 1985) se-
quence. A molecule represented using the SMILES sequence is comprised of characters
representing atoms or structure indicators. Mathematically, a molecule is represented as
IM = {m1,m2, . . . ,mLM }, where mi could be either an atom or a structure indicator,
and LM is the sequence length, which varies depending on a molecule. This molecule se-
quence is fed into the Molecule Transformers (Section 2.2), to produce a molecule encoding,
Menc ∈ REM . Another type of input, a protein with FASTA sequence, also consists of char-
acters of various amino acids. A formal protein representation is IP = {p1, p2, . . . , pLP },
where pj is one of the amino acids, and LP is the sequence length, which varies depending
on a protein. This protein sequence is the input of the Protein CNNs (Section 2.3) and
generates a protein encoding, Penc ∈ REP . Note that the encoding vector dimension EM
and EP are model parameters. Both of the encodings, Menc and Penc are together fed into
the multi-layered feed-forward network, Interaction Denses (Section 2.4), followed by the
last regression layer, which predicts the binding affinity scores.
4
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Figure 5: An example of molecule token embedding (MTE) and positional
embedding (PE) to make the model input xi for a given molecule sequence
of methyl isocyanate (CN=C=O).
2.2. Molecule Transformers
Molecule Transformers (Figure 2) are multi-layered bidirectional Transformer encoders based
on the original Transformer model (Vaswani et al., 2017). The Transformer can model a
sequence by itself without using a recurrent neural network (RNN) or CNN. Unlike these
previous sequence processing layers (RNN or CNN), Transformer can effectively encode
the relationship among long-distance tokens (atoms) in a sequence. This powerful context
modeling enables many Transformer-based NLP models to outperform previous methods in
many benchmarks (Vaswani et al., 2017; Devlin et al., 2018). Molecule Transformers is a
modification of the existing Transformer, BERT (Devlin et al., 2018), to better represent
a molecule by changing the cost function. Before plugging it into the proposed model
(Figure 1), we pre-train it using the modified masked language model task, which was
introduced in the BERT model (Devlin et al., 2018). Each Transformer block consists of
a self-attention layer and feedforward layer, and it takes embedding vectors as an input.
Therefore the first Transformer block needs to convert an input sequence into the form of
vectors using the input embedding.
2.2.1. Input Embedding
The input to the Molecule Transformers is the sum of the token embeddings and the position
embeddings. The token embeddings are similar to the word embeddings (Mikolov et al.,
2013), in that each token, mi is represented by a molecule token embedding (MTE) vector,
ei. These vectors are stored in a trainable weights MTE ∈ RVM×DM , where VM is the size
of the SMILES vocabulary and DM is the molecule embedding size. A MTE vector itself
is not sufficient to represent a molecule sequence with a self-attention network, because a
self-attention doesn’t consider the sequence order when calculating the attentions, unlike
other attention mechanisms. Therefore, we add a trainable positional embedding (PE)2,
pi ∈ RLmaxM ×DM , to ei that makes the final input representation, xi where LmaxM is the
maximum length of a molecule sequence, which is set to 100 in this study. This process is
illustrated in Figure 5.
2. Please refer to (Devlin et al., 2018) for more details.
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We add five special tokens to the SMILES vocabulary to make a raw molecule sequence
compatible with our model. [PAD] is for dummy padding to ensure the sequence has a fixed
length. [REP] is a representation token that is used when fine-tuning the Transformer in the
proposed MT-DTI model. [BEGIN]/[END] indicate the beginning or end of the sequence.
This token is useful for the model when dealing with a sequence longer than LmaxM . When it
is truncated on both sides, the absence of [BEGIN]/[END] tokens will serve as an effective
indicator of a truncation. Methyl isocyanate (CN=C=O), for example, can be represented
with 9 tokens;
[REP] [BEGIN] C N = C = O [END]
Each token is transformed into a corresponding vector by referencing MTE and PE.
2.2.2. Self-Attention Layer
These transformed input vectors, xi, are now compatible with an input to a self-attention
layer. Each self-attention layer is controlled by a query vector (qi), key vector (ki), and
value vector (vi), where i ∈ {0, 1, . . . , LmaxM }, all of which are different projections of the
input, X (xi ∈ RLmaxM ×DM ), using trainable weights, WQ ∈ RDM×Dq , WK ∈ RDM×Dk ,
and W V ∈ RDM×Dv , shown correspondingly in Figure 6. Then, the attention weights are
computed as:
Z = Attention(Q,K, V ) = softmax
(
QKT√
Dk
V
)
∈ RLmaxM ×Dv
Dk is the dimension of the key (one of the Z’s in Figure 7). Thus, the learned relationship
between the atoms can span the entire sequence via the self-attention weights.
2.2.3. Feed-Forward Layer
Similar to multiple filters in convolutional networks, a Transformer can have multiple atten-
tion weights, called multi-head attention. If one model has H-head attention, then it will
have Zh = Attention(XW
Q
h , XW
K
h , XW
V
h ), where h ∈ {1, 2, . . . ,H}. These H number of
attention matrices, Zh, are then concatenated (shown on the left of Figure 8) and projected
using WO ∈ RH·Dv×DM (shown on the middle of Figure 8) to form a final output of a
Transformer, Xout ∈ RLmaxM ×DM (shown on the right of Figure 8).
2.2.4. pre-training
We adopt one of the pre-training tasks of BERT (Devlin et al., 2018), the Masked Language
Model. Since the structure of molecule sequences are shown to be very similar to the
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structure of natural language sentences (Jastrzębski et al., 2016) and there are abundant
training examples, we hypothesize that predicting masked tokens is an effective way of
learning a chemical structure. We adopt a special token, [MASK], for this task. It replaces
a small portion of tokens so that the task of the pre-training model is to predict the original
tokens. We choose 15% of SMILES tokens at random for each molecule sequence, and
replace the chosen token with one of the special tokens, [MASK] with the probability of 0.8.
For the other 20% of the time, we replace the chosen token with a random SMILES token3
or preserve the chosen token, with an equal probability, respectively. The target label of
the task is the chosen token with the index. For example, one possible prediction task for
Methyl isocyanate (CN=C=O) is
input : [REP] [BEGIN] C N = [MASK] = O [END]
label : (C, 5)
2.2.5. Fine-tuning
The weights of the pre-trained Transformers (Section 2.2.4) are used to initialize the Molecule
Transformers in the proposed MT-DTI model (Figure 1). The output of the Transformers is
a set of vectors, where the size is equivalent to the number of tokens. To obtain a molecule
representation with a fixed length vector, we utilize the vector of the special token, [REP]
in the final layer. This vector conveys the comprehensive bidirectional encoding information
for a given molecule sequence, denoted as M rep ∈ RDM .
2.3. Protein CNNs
Another type of input to the proposed MT-DTI model is a protein sequence. We modified
the protein feature extraction module introduced by (Öztürk et al., 2018) by adding an
embedding layer for the input.4 It consists of multi-layer CNNs with an embedding layer to
make a sparse protein sequence continuous, and a pooling layer to represent a protein as a
fixed size vector. For a given protein sequence, Ip, each protein token, pj is converted to a
protein embedding vector by referencing trainable weights, PTE ∈ RVP×DP , where VP is the
size of the FASTA vocabulary and DP is the protein embedding size. Let P ∈ RLmaxP ×DP
be a matrix representing the input protein, where LmaxP is the maximum length of a protein
sequence, which is set to 1000 in this study. This protein matrix P is fed into the first
convolutional layer and convolved by the weights c1 ∈ Rs1×DP , where s1 is the length of
the filter. This operation is repeated m1 times with the same filter length. Then this first
convolution layer produces a vector PC1 ∈ RLmaxP −s1+1, where elements in PC1 convey the
s1-gram features across the sequence. Multiple convolutional layers can be stacked on top
of the previous output of the convolutional layer. After v number of convolution layers,
the final vector, PC1 ∈ R(LmaxP −s1−s2···−sv+v)×mv , is fed into the max pooling layer. This
max pooling layer selects the most salient features from the vectors produced by the filters
from the last layer. Then, the output of this max pooling layer is a vector P rep ∈ RDP
(mv = DP ).
3. Since the [MASK] token does not exist when testing, we need to occasionally feed irrelevant tokens when
training.
4. Adding an embedding layer slightly improves the accuracy of the DTI model.
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Dataset # of Compounds # of Proteins # of Interactions TRN DEV TST
DAVIS 68 442 30,056 20,037 5,009 5,010
KIBA 2,111 229 118,254 78,836 19,709 19,709
Table 1: Statistics of the Davis and Kiba datasets. TRN/DEV/TST: training, development,
evaluation sets.
2.4. Interaction Denses
A molecule representation (M rep ∈ RDM , Section 2.2.5) and a protein representation (P rep ∈
RDP , Section 2.3) are concatenated to create the input of Interaction Denses, MP rep ∈
RDM+DP . Interaction Denses approximates the affinity score through a multi-layered feed-
forward network with dropout regularization. The final layer is a regression layer associated
with the regression task for the proposed MT-DTI model. The weights of the network are
then optimized according to the mean square error between the network output (yˆ) and
actual affinity values (y).
3. Experiments
3.1. Datasets
3.1.1. Drug-Target Interaction
The proposed MT-DTI model is evaluated on two benchmarks, Kiba (Tang et al., 2014) and
Davis (Davis et al., 2011), because they have been used for evaluation in previous drug-target
interaction studies (Pahikkala et al., 2014; He et al., 2017; Öztürk et al., 2018). Davis is a
dataset comprised of large-scale biochemical selectivity assays for clinically relevant kinase
inhibitors with their respective dissociation constant (Kd) values. The original Kd values
are transformed into log space, pKd, for numerical stability, as suggested by (He et al., 2017)
as follows:
pKd = − log10(
kd
1e9
)
While Davis measures a bioactivity from one source of score, Kd, Kiba combines heteroge-
neous scores, Ki, Kd and IC50 by optimizing consistency among them. SimBoost (He et al.,
2017) filtered out proteins and compounds with less than 10 interactions for computational
efficiency, and we follow this procedure for a fair comparison. The number of compounds,
proteins and interactions of the two datasets are summarized in Table 1. To facilitate com-
parison and reproducibility, we followed the same 5-fold cross validation sets with a held-out
test set which is publicly available5.
3.1.2. pre-training Dataset
We downloaded the chemical compound information from the PubChem database (Gindu-
lyte et al., 2018)6. Only canonical SMILES information were used to maintain consistency
5. https://github.com/hkmztrk/DeepDTA/
6. ftp://ftp.ncbi.nlm.nih.gov/pubchem/Compound/CURRENT-Full/SDF/
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of representation. A total of 97,092,853 molecules are available in the canonical SMILES
format.
3.1.3. Drugbank Database
The DrugBank database comprises a bioinformatics and cheminformatics resource that pro-
vides known drug-target interaction pairs. To prove the effectiveness of drug candidates
generated by our model, we designed a case study (Section 4.1) using this database. We
extracted 1,794 drugs from the database, excluding any compounds that were used when
training our model. These selected compounds were the input to the trained model (by
Kiba dataset) along with a specific protein to generate corresponding Kiba scores. The
scores were used to find the best candidate drugs targeting that protein.
3.2. Training Details
Molecule Transformer is first trained with the collected compounds from the PubChem
database (Section 3.1.2), and then the trained Transformer is plugged into the MT-DTI
model for fine-tuning.
3.2.1. pre-training
We use 97 million molecules for pre-training. Before feeding it to the Molecule Transformer,
we tokenize each molecule at the character level. If the length of the molecules is more than
100, we truncate its head and tail together to have a fixed size of 100. We choose the middle
part of the longer sequence so that the model can easily distinguish truncated sequences by
simply looking at the existence of [BEGIN] and [END] tokens. The network structure of the
Molecule Transformer is as follows. The number of layers is 8, the number of heads is 8, the
hidden vector size is 128, the intermediate vector size is 512, the drop-out rate is 0.1, and
the activation is Gelu (Hendrycks and Gimpel, 2016). These parameters are picked from
preliminary experiments and the hyperparameters used in the NLP model, BERT (Devlin
et al., 2018). We hypothesized that finding a chemical structure might be roughly 2-4 times
easier task than finding a language model, because the size of the SMILES vocabulary
is smaller than natural languages (70 vs 30k). Although the SMILES vocabulary is 400
times simpler, the number of tokens in the PubChem molecule datasets is about 2.4 times
more than what BERT used to pre-train (8B vs 3.3B). This indicated that the molecules
might have more complexity than expected when only considering the size of the vocabulary.
Therefore we used parameters that were 2-4 times smaller than BERT. We note that there
may be other parameter sets that can yield even better performance. We use the batch size
of 512 and the maximum token size of 100, which enables it to process 50K tokens in one
batch. Considering the average length of the compound sequence is around 80, there are
approximately 8 billion tokens in the training corpus. We pre-train Molecule Transformer
for 6.4M steps, which is equivalent to 40 epochs (8B/50K*40=6.4M). With an 8-core TPU
machine, the pre-training took about 58 hours. The final accuracy of the Masked LM task
was about 0.9727, which is comparable to the 0.9855 achieved by BERT on natural language.
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3.2.2. fine-tuning
The specifications of the Molecule Transformer in the MT-DTI model are the same as the
one used when pre-training (Section 3.2.1). The Protein CNNs (Section 2.3) consists of one
embedding layer, three CNN layers, and one max pooling layer. It uses 128-dimensional
vectors for the embedding layer. For CNN blocks, we denote the filter size as K and the
number of the filter as L. The final model parameter settings of CNNs are K1,K2,K3 =
12(Kiba), 8(Davis) and L1 = 32, L2 = 64, L3 = 96. The max pooling layer selects the
best token representations from the last CNN layer, which makes the feature length as 96.
Interaction Dense (Section 2.4) is comprised of three feed-forward layers and one regression
layer. The layer sizes, when training Kiba, are 1024, 1024, 512 in order of the feature input to
the regression layer and the learning rate, γ, is 0.0001. We reduced the network complexity
when training Davis due to the small number of training samples. We use two feed-forward
layers of sizes 1024 and 512. The learning rate is adjusted to 0.001. The entire network uses
the same dropout rate of 0.1. All the hyper-parameters are tuned based on the lowest mean
square error of the development sets for each fold, and the final score is evaluated on the
held-out test set with the model at 1000 epochs.
3.3. Evaluation Metrics
We use four metrics to evaluate the proposed model: mean squared Error (MSE), concor-
dance index (CI) (Gönen and Heller, 2005), r2m, and area under the precision-recall curve
(AUPR). MSE is a typical loss in the optimizer. CI is the probability that the predicted
scores of two randomly chosen drug-target pairs, yi and yj , are in the correct order:
CI =
1
N
∑
yi>yj
h(yˆi > yˆj),
where N is a normalization constant (the number of data pairs) and h(·) is a step func-
tion (Öztürk et al., 2018):
h(x) =

1, x > 0
0.5 x = 0
0, else
The r2m (Pratim Roy et al., 2009; Roy et al., 2013) index is a metric for quantitative structure-
activity relationship models (QSAR models). Mathematically,
r2m = r
2 ∗ (1−
√
r2 − r20),
where r2 and r20 are the squared correlation coefficients with and without intercept, respec-
tively. An acceptable model should produce an r2m value greater than 0.5. Since AUPR is
a metric for binary classification, we transform the regression scores to binary labels using
known threshold values (He et al., 2017; Tang et al., 2014). For Davis, pairs with pKd ≥ 7 are
marked as binding (1), others as no binding (0), and for Kiba, pairs with KIBA score ≥ 12.1
are marked as binding (1), others as no binding (0).
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Datasets Method CI (std) MSE r2m (std) AUPR (std)
Kiba
KronRLS 0.782 (0.001) 0.411 0.342 (0.001) 0.635 (0.004)
SimBoost 0.836 (0.001) 0.222 0.629 (0.007) 0.760 (0.003)
DeepDTA 0.863 (0.002) 0.194 0.673 (0.009) 0.788 (0.004)
MT-DTIw/oFT 0.844 (0.001) 0.220 0.584 (0.002) 0.789 (0.004)
MT-DTI 0.882(0.001) 0.152 0.738(0.006) 0.837(0.003)
Davis
KronRLS 0.871 (0.001) 0.379 0.407 (0.005) 0.661 (0.010)
SimBoost 0.872 (0.002) 0.282 0.644 (0.006) 0.709 (0.008)
DeepDTA 0.878 (0.004) 0.261 0.630 (0.017) 0.714 (0.010)
MT-DTIw/oFT 0.875 (0.001) 0.268 0.633 (0.013) 0.700 (0.011)
MT-DTI 0.887(0.003) 0.245 0.665(0.014) 0.730(0.014)
Table 2: Test set results of the proposed MT-DTI model, MT-DTI model without fine-tuning
(denoted as MT-DTIw/oFT ), and other existing approaches.
3.4. Baselines
For the baseline methods, two similarity-based models and one deep learning-based model,
the current SOTA, are tested. One of the similarity-based models is KronRLS (Pahikkala
et al., 2014), whose goal is to minimize a typical squared error loss function with a special
regularization term. The regularization term is given as a norm of the prediction model,
which is associated with a symmetric similarity measure. Another similarity-based model
is Simboost (He et al., 2017), which is based on a gradient boosting machine. Simboost
utilizes many kinds of engineered features, such as network metrics, neighbor statistics,
PageRank (Page et al., 1999) scores, and latent vectors from matrix factorization. The
last one is a deep learning model, which is the SOTA method in predicting drug-target
interactions, called DeepDTA (Öztürk et al., 2018). It is an end-to-end model that takes a
pair of sequences, (molecule, protein), and directly predicts affinity scores from the model.
Features are automatically captured through back propagation of the multi-layered convo-
lutional neural networks.
3.5. Results
The comparisons of our proposed MT-DTI model to the previous approaches are shown in
Table 2. Reported scores are measured on the held-out test set using five models trained
with the five different training sets. The best model parameters are selected based on
the development set scores. MT-DTI outperforms all the other methods in all of the four
metrics. The performance improvement is more noticeable when when there are many
training data where the improvements of Kiba are 0.019, 0.042, 0.065, and 0.04 compared
with Davis’s improvements of 0.009, 0.016, 0.035, and 0.016, for CI, MSE, r2m, and AUPR,
respectively. Furthermore, our model tends to be more stable with a larger training set,
with the lowest standard deviation for CI and AUPR. Another interesting point is that
our method without fine-tuning (MT-DTIw/oFT in Table 2) produced competitive results.
It outperforms the similarity based metrics and performs better than Deep-DTA for some
metrics. This suggests that the molecule representation using pre-training learns some useful
chemical structure that can be exploited by the interaction denses model.
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4. Case Study
We performed a case study using actual FDA-approved drugs targeting a specific protein,
epidermal growth factor receptor (EGFR). This protein is chosen because this is one of the
famous genes related to many cancer types. We calculated the interaction scores between
EGFR and the 1,794 selected molecules based on the DrugBank database (see Section 3.1.3
for the details). These scores are sorted in descending order and summarized in Table 3.
EGFR is a transmembrane protein that is activated by binding of ligands such as epi-
dermal growth factor (EGF) and transforming growth factor alpha (TGFa) (Herbst, 2004).
Mutations in the coding regions of the EGFR gene are associated with many cancers, in-
cluding lung adenocarcinoma (Sigismund et al., 2018). Several tyrosine kinase inhibitors
(TKIs) have been developed for the EGFR protein, including gefitinib, erlotinib, and afa-
tinib. More recently, Osimertinib was developed as a third generation TKI targeting the
T790M mutation in the exon of the EGFR gene (Soria et al., 2018). Since the direct binding
of these drugs to EGFR protein is well known, we tested whether our proposed model can
identify known drugs for the EGFR protein.
4.1. Biological Insights
The result indicated that our model successfully identified known EGFR targeted drugs as
well as novel chemical compounds that were not reported for association with the EGFR
protein. For example, the first and second generation TKIs, such as Erlotinib and Gefitinib,
and Afatinib, respectively, were predicted to exhibit high affinity to the EGFR protein (Ta-
ble 3). Lapatinib (Medina and Goodin, 2008), which inhibits the tyrosine kinase activity
associated with two oncogenes, EGFR and HER2/neu (human EGFR type 2), was predicted
to exhibit the highest affinity. Osimertinib was also identified. Interestingly, chemical com-
pounds targeting opioid receptors (naltrexone hydrochloride, nalbuphine hydrochloride, and
oxycodone hydrochloride trihydrate) for pain relief, antihistamines (methdilazine hydrochlo-
ride and astemizole), antipsychotic medication for schizophrenia (Prolixin Enanthate and
Asenapine), and corticosteroids for skin problems (Triamcinolone acetonide sodium phos-
phate, Oxymetazoline hydrochloride, Desonide) were predicted to be associated with EGFR.
Among these chemical compounds, Astemizole was suggested as a promising compound when
treated with known drugs for lung cancer patients (Ellegaard et al., 2016; de Guadalupe
Chávez-López et al., 2017). Therefore, further investigations of these chemicals may provide
a new therapeutic strategy for lung cancer patients.
5. Related Work
Predicting drug-target interaction traditionally focused on a binary classification prob-
lem (Yamanishi et al., 2008; Bleakley and Yamanishi, 2009; van Laarhoven et al., 2011;
Cao et al., 2012; Gönen, 2012; Cobanoglu et al., 2013; Cao et al., 2014; Öztürk et al., 2016).
The most recent approach tackling this binary classification problem is an interpretable deep
learning based model (Gao et al., 2018). Although these methods show promising results
on binary datasets, they are simplifying protein-ligand interactions by thresholding affinity
values. In order to model these complex interactions, several methods have been proposed,
which can be categorized into three kinds. The first category of these models is molecu-
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Ranking Compound ID Compound Name KIBA Score
1 208908 Lapatinib∗ 14.002403
2 11557040 Lapatinib Ditosylate∗ 13.811217
3 10184653 Afatinib∗ 13.404812
4 16147 Triamcinolone Acetonide Sodium Phosphate 13.147043
5 5485201 Naltrexone Hydrochloride 13.114577
6 123631 Gefitinib∗ 13.111686
7 60699 Topotecan Hydrochloride 13.108758
8 5360515 Naltrexone 13.065864
9 441351 Rocuronium Bromide 13.032806
10 6918543 Almitrine Mesylate 13.016999
11 176870 Erlotinib∗ 12.885199
12 23422 Tubocurarine Chloride Pentahydrate 12.87076
13 6000 Tubocurarine 12.809549
14 11954379 Erlotinib Variant∗ 12.782704
15 11954378 Erlotinib Hydrochloride∗ 12.768639
16 3389 Prolixin Enanthate 12.737285
17 23724988 Oxycodone Hydrochloride Trihydrate 12.709352
18 14676 Methdilazine Hydrochloride 12.662965
19 5281065 Ibutilide Fumarate 12.650397
20 9869929 Avanafil 12.635439
21 60700 Topotecan 12.618897
22 5360733 Nalbuphine Hydrochloride 12.610958
23 5282487 Paroxetine Hydrochloride Hemihydrate 12.608804
24 66259 Oxymetazoline Hydrochloride 12.557486
25 5311066 Desonide 12.538858
26 2247 Astemizole 12.536284
27 11954293 Asenapine 12.534941
28 11304743 Riociguat 12.527533
29 82153 Flunisolide 12.527164
30 71496458 Osimertinib∗ 12.507524
Table 3: Compound ranking based on the predicted Kiba scores when the target is EGFR
protein. All compounds are from Drugbank database excluded any compounds in Kiba
dataset. [Compound Name]∗ represents a known EGFR targetting drug.
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lar docking (Trott and Olson, 2010; Luo et al., 2016), which is a simulation-based method.
These methods are not scalable, due to heavy preprocessing. To overcome this downside, the
second category, similarity-based methods, was proposed. They are KronRLS (Pahikkala
et al., 2014) and SimBoost (He et al., 2017), which is based on the calculation of similarity
matrix of inputs. With the advent of deep learning, two deep learning-based methods have
been proposed (Gao et al., 2018; Öztürk et al., 2018). Like these models, our model is also
based on deep learning, but our proposed model has a better molecule representation, and
improves its performance through a transfer learning technique.
Deep learning-based transfer learning, pre-training and fine-tuning, have been applied to
various tasks such as computer vision (Rothe et al., 2015; Ghifary et al., 2016), NLP (Howard
and Ruder, 2018), speech recognition (Jaitly et al., 2012; Lu et al., 2013), and health-care
applications (Shin et al., 2017). The idea is to use appropriate pre-trained weights to improve
results in corresponding tasks, which also can be found in our experimental results.
6. Discussion
This paper proposes a new molecule representation using the self-attention mechanism,
which is pre-trained using publicly available big data of compounds. The trained parameters
are transferred to our DTI model (MT-DTI) so that it can be fine-tuned using two DTI
benchmark data. Experimental results show that our model outperforms all other existing
methods with respect to four evaluation metrics. Moreover, the case study of finding drug
candidates targeting a cancer protein (EGFR) shows that our method successfully enlists all
of the existing EGFR drugs in top-30 promising candidates. This suggests our DTI model
could potentially yield low-cost drugs and provide personalized medicines. Our model can be
further improved as the proposed attention mechanism is also applied to represent proteins.
However, we didn’t explore this direction for two reasons. One reason is that the length
of a protein sequence is ten times longer than a molecule sequence on average, which takes
a considerable amount of time for computation. Another reason is the need for a protein
dataset which contains enough sufficient information to pre-train the model. Unfortunately,
such dataset is not readily available.
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